RecruitingACTRN12614001143617

Determining Circulating Tumour Cells (CTC) and other rare cells in cancer patients and for early detection screening

Determining Circulating Tumour Cells (CTC) and other rare cells in cancer patients before and after treatment and for early detection screening using ISET (Isolation by Size of Epithelial/ Trophoblastic Tumour Cells) technology

Sponsor

Dr Karin Ried

Enrollment

2,000 participants

Start Date

Oct 6, 2014

Study Type

Observational

Conditions

Chronic illness due to infection Cancer

Summary

Treatment effectiveness: This study will determine whether there is a difference between the number and type of circulating tumour cells in cancer patients before and after treatment. Who is it for? You may be eligible to join this study if you are aged 18-80 years, diagnosed with any cancer and have received treatment at least 3 weeks ago or will receive treatment within one week. Study details The study aims to establish the Circulating Tumour Cell (CTC) detection method using the ISET (Isolation by Size of Epithelial/Trophoblastic Tumour Cells) device (Rarecells, France) in conjunction with cancer therapies offered at National Institute of Integrative Medicine. There will be no changes to the participants’ cancer treatment plans. Participants will be required to provide a blood sample at the beginning of their treatment and 3 months after commencement of treatment. The blood will be processed using the ISET technology to determine the number and types of circulating tumour cells. Early detection screening: This component of the study aims to determine whether the ISET-ED screening blood test can be used for early detection of cancer. Who is it for? You may be eligible to join this part of the study if you are aged between 18-80 years and have a family history of cancer, or have been diagnosed with chronic disease, or are attending a health check. Study details: Participants in this part of the study will undergo a blood test at baseline and at 3 months. The ISET-ED (early detection screening) test has the potential to detect potentially malignant cells, and other illness causing rare cells.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

This study is investigating whether a blood test can detect cancer cells circulating in the bloodstream (called Circulating Tumour Cells or CTCs), and whether tracking these cells can show how well cancer treatment is working. The test uses a device called ISET that filters blood to capture rare cancer cells. The study is also exploring whether this same test could be used to detect cancer early in people at high risk, such as those with a family history of cancer. You may be eligible if: - You are between 18 and 80 years old - You have been diagnosed with any type of cancer, OR - You have a family history of cancer, a chronic illness, or are attending a health check-up You may NOT be eligible if: - There are no specific exclusion criteria for this study Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Monitoring test: Circulating tumour cells are isolated from blood (10 ml in ACD) by ISET (Isolation by Size of Epithelial Tumour Cells) using filtration technology and analysed within one week before

Monitoring test: Circulating tumour cells are isolated from blood (10 ml in ACD) by ISET (Isolation by Size of Epithelial Tumour Cells) using filtration technology and analysed within one week before treatment (baseline) and at 3 months after treatment cycle commenced and at least 3 weeks after treatment cycle ceased (follow-up) - primary outcome measure Follow-up at 6 months, 9 months and 12 months, if applicable (secondary outcome measures) Screening test: Early detection in patients with a family history of cancer or patients with chronic disease, or as part of a health check. The ISET-ED (early detection screening) test has the potential to detect potentially malignant cells, and other illness causing rare cells. Circulating rare cells are isolated from blood (10 ml in ACD) by ISET technology and analysed at baseline and at 3-12 months (follow-up)